We analyzed sera from 28 patients with various types of malignancies for the occurrence of antibodies against exotoxin A of Pseudomonas aeruginosa and two Pseudomonas proteases. A total of 27 of these individuals were colonized or infected with P. aeruginosa at one time or another during the study, whereas the remaining patient was colonized with four non-P. aeruginosa species of Pseudomonas. Sera were obtained from several of these patients before P. aeruginosa colonization or infection of these individuals was detected, which provided an opportunity to evaluate their responsiveness to pseudomonal exoproducts as they acquired the organism. Exotoxin A was purified from culture supernatant fluids of strain PA-103, and the two proteases were purified from an isolate of strain JR3, a highly proteolytic strain originally recovered from the sputum of a cystic fibrosis patient. Antibodies to the exotoxin A and the two proteases were detected in these sera, and sera which contained relatively high antibody levels to exotoxin A afforded mice complete protection against lethal challenges with this substance. Statistical analyses showed that patients infected with P. aeruginosa had consistently higher antibody levels (P < 0.005) to the exoproducts than patients who were colonized with this organism. Also, patients colonized with P. aeruginosa possessed significantly higher antibody levels (P < 0.003) to these three exoproducts than uninfected, hospitalized patients. Parke-Davis type 1 was the strain most commonly isolated from these patients (46%), but colonization or infection due to this organism usually resulted in the production of low levels of antibody to Pseudomonas exoproducts. However, infections with Parke-Davis type 7 organisms were always associated with intermediate-and high-responder sera to exotoxin A. These results indicated that potentially toxic products were elaborated during the course of cancer-related colonization and infection with P. aeruginosa.
factors produced by P. aeruginosa have been isolated and purified, the role of these components in disease processes is not clear. Among the most closely examined of these factors are the hemolysins, several proteolytic enzymes, a potent exotoxin (exotoxin A), whose mechanism of action is strikingly similar to that of diphtheria toxin, and lipopolysaccharide, which is always associated with gram-negative bacteria. All of these compounds are capable of producing deleterious effects in various in vivo and in vitro systems (2, 9, 10, 14, 16, 18) .
Relatively little is known about the antibody responses of humans to these proposed virulence factors. Pollack et al. (19, 20) have shown that neutralizing and hemagglutinating antibodies to exotoxin A are present in the sera of individuals with P. aeruginosa infections. Klinger et al. (11) recently demonstrated that antibodies to exotoxin A and two Pseudomonas proteases are present in the sera of cystic fibrosis (CF) patients. Diaz et al. (4) have shown that antibodies to P. aeruginosa cell wall-associated antigens are present in CF patients, and Pollack and Young (21) have shown that anti-exotoxin A antibodies and anti-lipopolysaccharide antibodies are often present in the sera of patients with Pseudomonas septicemia. More importantly, these authors demonstrated that survival is significantly greater in patients who have relatively high levels of both anti-exotoxin A antibodies and anti-lipopolysaccharide antibodies.
In light of the finding that proteases play a prominent role in some models of experimental P. aeruginosa infection (4, 18) , it would be of considerable interest to determine whether antibodies to these proteases (as well as exotoxin A) are present in the sera of cancer patients who have been infected or colonized with P. aeruginosa. All of the patients in the study described below suffered from some type of malignancy, and all but one at one time or another had been colonized or infected with P. aeruginosa. An additional aspect of this study was to ascertain whether antibodies against exotoxin A, as detected by a radioimmunoassay (RIA), protected mice against experimental lethal challenges with this substance. MATERIALS 22 of the patients studied were represented by more than one serum sample. P. aeruginosa isolates were typed by using Parke-Davis typing antiserum (5) . Routine cultures, including rectal, vaginal, skin, and throat swabs, were taken for all patients. In addition, stools, blood, urine, and sputum were examined for the presence of P. aeruginosa. During autopsies, biopsies were performed routinely on the lungs, spleens, and livers, and these tissues were examined for the presence of P.
aeruginosa. If P. aeruginosa was found consistently in the lungs, blood, or urine in concentrations greater than 100,000 cells per ml, a patient was considered infected. If P. aeruginosa was found in vaginal, rectal, skin, and throat swabs in low numbers (see below) and was present in low numbers in stool and urine samples (less than 100,000 cells per ml), a patient was considered colonized. P. aeruginosa isolates were quantitated by clock streaks of swabs or by blood and urine colony counts from pour plates by both methods. Scores of 1+, 2+, 3+, and 4+ refer to growth in various areas of a four-way clock streak on blood agar; growth only in the first quadrant was recorded as 1 +, growth in both the first quadrant and the second quadrants was recorded as 2+, and so on.
Exotoxin A and proteases. The purification and characterization of exotoxin A and proteases have been described previously (11) . A reference sample of exotoxin A further purified by preparative electrophoresis (12) was provided by Stephen Leppla, U.S. Army Institute of Medical Research, Ft. Detrick, Md. Experiments with this exotoxin A sample gave RIA indices similar to the indices obtained when our toxin preparation was used; however, the absolute counts obtained when the toxin from Leppla was used were usually 10 to 20% higher. Protease I corresponded to DEAE peak I of Morihara et al. (15) and had a molecular weight of 20 x 103 based on its elution volume from Sephadex G-100. Protease II eluted at a molecular weight of approximately 30 x 103 and corresponded to DEAE peak II (elastase) of Morihara et al. (15) . Each protease migrated as a single band on polyacrylamide gels (7), and each was immunologically distinct from the other as determined by gel immunodiffusion.
RIA. The solid-phase RIA in microassay trays has been described previously (11) . The indices obtained in this study were derived from assays in which both the test sera and the control serum were diluted 1:100. All RIA data were expressed as a ratio of the counts per minute of bound '25I-labeled anti-human immunoglobulin per test serum to the counts per minute of control serum pool 5 for each of the three P. aeruginosa exoproducts. The control pool consisted of equal volumes of sera from six randomly selected, uninfected, hospitalized adults and has been described previously (11 b By comparing means and standard deviations (13), we found that the antibody levels against all three antigens in both infected and colonized patients (Table  2) were significantly higher (P < 0.003) than comparable levels in control sera. Also, antibody levels against these same three exoproducts in infected patients were significantly higher (P < 0.005) than levels in colonized patients. data, we found that the antibody levels in the sera from infected and colonized patients were significantly higher than the levels in the control sera (confidence limits, 99.7%). Also, the antibody levels in the sera from infected patients were significantly higher than the antibody levels in the sera from colonized patients (confidence limits, 99.5%).
Serology and colonization versus infection status of the patients. The Parke-Davis designations for the isolates are shown in Table 2 . Of the 37 different P. aeruginosa isolates, 13 were ParkeDavis type 1. This meant that of the 28 patients examined, 13 (46%) had type 1 organisms isolated from them at least once during the study. Although the type 1 organisms were the most common isolates, the majority of these infections or colonizations resulted in low-responder antisera ( indices to all three exoproducts by time of the first serum withdrawal and no isolatable P. aeruginosa. After P. aeruginosa was isolated from a skin lesion and eventually from the blood, the RIA index for exotoxin A increased from 1.0 to 1.6, and the RIA indices for proteases I and II increased from 0.9 to 2.8 and from 1.3 to 1.9, respectively. Passive protection against exotoxin A. To determine whether sera from patients containing intermediate and high levels of anti-exotoxin A antibodies were indeed protective, we tested serum samples from three patients (chosen at random, one from each responder category) for the ability to protect mice against lethal challenges with exotoxin A. At 4 h before challenge with the exotoxin, each mouse received 0.25 ml of a dilution of patient serum intraperitoneally. Then each mouse was challenged by intravenous administration of 0.1 ml of exotoxin A containing four 50% lethal doses, as previously described. These data are shown in Table 4 (22, 24) that most patients who develop nonbacteremic P. aeruginosa infections have preexisting, chronic pulmonary disease or some other form of severe medical disorder; that is, P. aeruginosa infections usually occur only in severely debilitated or compromised hosts. This is particularly evident in patients with CF, cancer, and severe burns. Recently, we examined the sera of CF patients for the production of antibody against the three exoproducts described above (11) . In that study, we demonstrated an inverse correlation between the ratio for each of the Pseudomonas exoproducts and the clinical (Schwachman) score; that is, the highest ratios occurred in the patients who had the lowest clinical scores.
On the other hand, cancer patients pose an entirely different problem than individuals who have CF. The frequency of P. aeruginosa infections is very high among cancer patients, especially at institutions that possess special cancer units (6) . This high frequency may be due to the fact that patients with acute leukemia and other VOL. 15, 1982 on June 24, 2017 by guest http://jcm.asm.org/ Downloaded from bone marrow disorders are usually deficient in neutrophils (25) . Neutropenia can also occur less frequently in patients with other forms of cancer and is usually secondary to chemotherapy; hence, it is not as severe or prolonged (25) . This may be in part responsible for the fact that the RIA indices in this study were generally lower than the indices observed with CF patients (11) . Individuals with neutropenia usually have impaired phagocytic capabilities, and this certainly affects their ability to process an antigenic stimulus. Indeed, despite the fact that the data were collected in the same manner, the RIA indices in this study were generally lower than the indices observed with CF patients. Individuals with CF characteristically have chronic, pulmonary infections with P. aeruginosa which can last for many years, but the disease state does not seem to impair the ability of these patients to respond immunologically. In contrast, P. aeruginosa infections of cancer patients appear to be of much shorter duration, and this could be another explanation for the lower RIA values against the various P. aeruginosa exoproducts found in cancer patients. A certain degree of fluctuation was present in the data expressing the antibody responses to the three antigens which we tested. This was most likely due to a number of factors, such as the duration of the infection and the immune status of these individuals. Generally, most of the responses shown in Table 1 are responses of low to intermediate capability; this was probably a reflection of the inability of the patients to respond immunologically. One important fact shown by these data is that a significant and detectable level of antibody to one or more of the P. aeruginosa exoproducts was present in the sera of almost all of these patients, regardless of whether the patients were merely colonized or actually infected (P < 0.003). Of course, the infected patients showed significantly higher antibody responses against the three exoproducts than the colonized patients (P < 0.005). This provides at least suggestive evidence that these exoproducts are produced during the course of colonization and infection with this organism.
The serotype distribution of P. aeruiginosa observed in this study is worth further mention (Table 2) . We found that the most common type of P. aeruginosa isolated from the cancer patients whom we studied was Parke-Davis type 1. A total of 46% of the patients in this study were either infected or colonized with this type of P. aeruginosa. The majority of the P. aeruginosa blood isolates (39%) from bacteremic patients in the study of Pollack and Young (21) Table 3 shows the results of a sequential study on three patients over a period of several months. P. aeruginosa had not been isolated from these patients at the time that the first serum samples were drawn, but it was isolated by the time that subsequent samples were taken. As was the case for these and other patients from whom P. aeruginosa was isolated throughout the entire course of hospitalization, the general trend was for the antibody response to a particular antigen to increase after the isolation of the organism. These The concept of increasing titers against exotoxin A in patients infected with P. aeruginosa agrees well with the results of our previous study on CF patients (11) and also the results of Pollack and Taylor (20) and Pollack et al. (19) . In addition, anti-exotoxin A produced in rabbits passively protects against lethal P. aeruginosa burn infections in mice when the infecting organism is a toxin producer (17) but not when it is atoxigenic. It has also been shown (16) that passive immunization with rabbit antitoxin prevents toxin-mediated protein synthesis inhibition in mice, which occurs in unimmunized animals infected with toxin-producing P. aeruginosa strains. Finally, Pollack and Young (21) have shown that antibodies against exotoxin A (as well as P. aeruginosa lipopolysaccharide) are present in the sera of patients with P. aeruginosa septicemia and that the presence of these antibodies is associated with survival. This is the first report of the production of antiprotease antibodies in cancer patients and also one of the first reports demonstrating that humans infected with P. aeruginosa can produce antibodies against exotoxin A that are capable of protecting experimental animals against lethal challenges with that substance.
